Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial
| Autor: | Marcelo Sánchez, Pere Gascón, Josep Eugeni Herrero, Carlos Conill, Begoña Mellado, Josep Malvehy, Teresa Castel, María González Cao, Rosa M. Martí, Susana Puig |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Interleukin 2
Adult Male Cancer Research medicine.medical_specialty Skin Neoplasms Dacarbazine Neutropenia Vinblastine Gastroenterology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Immunologic Factors Melanoma Aged Cisplatin business.industry Interferon-alpha General Medicine Middle Aged medicine.disease Survival Analysis Surgery Regimen Oncology Toxicity Interleukin-2 Female business medicine.drug |
| Zdroj: | Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 7(6) |
| ISSN: | 1699-048X |
| Popis: | Metastatic melanoma has an ominous prognosis. Bio-chemotherapy regimens can increase the response rate but with a high degree of toxicity due, mainly, to the use of high-dose intravenous interleukin-2. To test the feasibility and activity profile of a bio-chemotherapy regimen of low-dose subcutaneous interleukin-2. Administration scheme: dacarbazine at 200 mg/m2/d on days 1–4, cisplatin at 20 mg/m2/d intravenous on days 1–4, vinblastine at 1.5 mg/m2/d on days 1–4, IL-2 at 4.5 MUI/m2/d subcutaneous on days 5–8, IFN-alpha at 5 MU subcutaneous on days 5–9, 11, 13, 15 of every 21-day cycle. Objective response was obtained in 11 patients (39.3%; 95%CI: 21–59) including 4 with complete response (14.5%; 95%CI: 4–33). With an extended follow-up of 49 months and 60 months, respectively, 2 patients continue with complete response. The main toxicities were haematological: grade 3–4 neutropenia in 8.2% of cycles, thrombocytopenia in 1.2% and anaemia in 3.2%. The regimen is safe and has a good activity profile. The presence of long-term survivors, despite the use of lower doses and subcutaneous IL-2, is encouraging. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink